Skip to content
Research Article Open access CC BY 4.0

A Subset of Genes Can Distinguish between Bortezomib Responsive Versus Bortezomib Resistant Myeloma

Yossi Cohen, Odit Gutwein, Osnat Garach- Jehoshua, Adina Bar-Haim, Abraham Kornberg

Journal of Advances in Medicine and Medical Research · pp. 1271–1279 · Published 5 Nov 2014

10.9734/BJMMR/2015/13421

Abstract

Despite the widespread use of proteasome inhibitors in the treatment of multiple myeloma, the mechanisms of the anti-myeloma activity and the molecular pathways that execute the tumor cell killing are still unknown. In the present work we compared gene expression profile changes in response to bortezomib treatment of cultured bone marrow samples from patients with bortezomib-sensitive versus bortezomib-resistant myeloma. The results showed a pronounced induction of>70 genes including>30 heat shock protein transcripts in both patient groups and therefore debate the anti-tumor action, attributed to the unfolded protein response. In contrast, a subset of 7 genes (MMP12, IL7R, MGST1, C3, CYP27A1, MIR148A and CXXC4) changed only in the samples from the bortezomib-sensitive cases and therefore these tumor-associated genes might serve as predictors of the treatment efficacy, as well as for making of further insights onto the mechanism of action of proteasome inhibitors. In summary, we identified a subset of 7 genes which distinguished in our small series betweensensitive versus resistant tumor cells to bortezomib, which requires further assessment in a larger cohort of patients.

Multiple myeloma gene expression profile MMP12 heat shock proteins IL7R

References (49)

  1. 1 XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor [DOI]
  2. 2 XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response [DOI]
  3. 3 Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response [DOI]
  4. 4 ER stress-induced cell death mechanisms [DOI]
  5. 5 Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating Bcl2 and Perturbing the Cellular Redox State [DOI]
  6. 6 Plasma cell differentiation requires the transcription factor XBP-1 [DOI]
  7. 7 Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells [DOI]
  8. 8 NF-κB as a Therapeutic Target in Multiple Myeloma [DOI]
  9. 9 Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1 [DOI]
  10. 10 Molecular sequelae of proteasome inhibition in human multiple myeloma cells [DOI]
  11. 11 Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis [DOI]
  12. 12 Role of the unfolded protein response in cell death [DOI]
  13. 13 Proteasome-dependent endoplasmic reticulum-associated protein degradation: An unconventional route to a familiar fate [DOI]
  14. 14 Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. [DOI]
  15. 15 Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells [DOI]
  16. 16 Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib [DOI]
  17. 17 Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition [DOI]
  18. 18 Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma [DOI]
  19. 19 Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells [DOI]
  20. 20 Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis [DOI]
  21. 21 Activation of an Unfolded Protein Response during Differentiation of Antibody-secreting B Cells [DOI]
  22. 22 The X‐box binding protein‐1 transcription factor is required for plasma cell differentiation and the unfolded protein response [DOI]
  23. 23 Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells [DOI]
  24. 24 Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications [DOI]
  25. 25 Mitochondrial-Mediated Disregulation of Ca2+ Is a Critical Determinant of Velcade (PS-341/Bortezomib) Cytotoxicity in Myeloma Cell Lines [DOI]
  26. 26 Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress [DOI]
  27. 27 Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells [DOI]
  28. 28 The resistance mechanisms of proteasome inhibitor bortezomib [DOI]
  29. 29 The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group [DOI]
  30. 30 Using transcriptome sequencing to identify mechanisms of drug action and resistance [DOI]
  31. 31 The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib [DOI]
  32. 32 Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells [DOI]
  33. 33 Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells [DOI]
  34. 34 Advances in the understanding of mechanisms and therapeutic use of bortezomib.
  35. 35 The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 [DOI]
  36. 36 Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition [DOI]
  37. 37 Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells [DOI]
  38. 38 Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications [DOI]
  39. 39 Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model [DOI]
  40. 40 Macrophage Metalloelastase (MMP12) Regulates Adipose Tissue Expansion, Insulin Sensitivity, and Expression of Inducible Nitric Oxide Synthase [DOI]
  41. 41 Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma [DOI]
  42. 42 Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib [DOI]
  43. 43 Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells [DOI]
  44. 44 In Vivo Stimulation of IκB Phosphorylation Is Not Sufficient To Activate NF-κB [DOI]
  45. 45 Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia [DOI]
  46. 46 The proliferation arrest of primary tumor cells out-of-niche is associated with widespread downregulation of mitotic and transcriptional genes [DOI]
  47. 47 Niche-modulated and niche-modulating genes in bone marrow cells [DOI]
  48. 48 Cutting Edge: Proteasome Involvement in the Degradation of Unassembled Ig Light Chains [DOI]
  49. 49 Ubiquitination and Degradation of the Inhibitors of NF- B [DOI]

Cited by 1

High cholesterol increases myeloma tumour burden and promotes resistance to bortezomib

Beatriz Gámez, Danielle Whipp, Srinivasa R. Rao · bioRxiv (Cold Spring Harbor Laboratory) · 2025

Article metrics

Real usage data collected on this platform.

68

Page views

0

PDF downloads

36

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.